Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers.
Malhotra L et al.
Journal of Biomolecular Structure & Dynamics, 2025
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
Germline variant affecting p53β isoforms predisposes to familial cancer.
Schubert SA et al.
Nature Communications, 2024
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
Prevalence of the cancer-associated germline variants in Russian adults and long-living individuals: using the ACMG recommendations and computational interpreters for pathogenicity assessment.
Gusakova M et al.
Frontiers in Oncology, 2024
TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited.
Shin DY
Cancers, 2023
The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression.
Cai BH et al.
Biomedicines, 2023
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status.
Reder H et al.
Cancer Medicine, 2021
Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation.
Cai BH et al.
International Journal of Molecular Sciences, 2019
Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.
Wong K et al.
Nature Communications, 2019
The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants.
Omar SI et al.
Oncotarget, 2018
Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain.
Ouaray Z et al.
Proteins, 2016
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells.
Menendez D et al.
Oncotarget, 2016
Structural Basis for p53 Lys120-Acetylation-Dependent DNA-Binding Mode.
Vainer R et al.
Journal of Molecular Biology, 2016
Activation of p53 Facilitates the Target Search in DNA by Enhancing the Target Recognition Probability.
Itoh Y et al.
Journal of Molecular Biology, 2016
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.
Beckerman R et al.
Cell Cycle (georgetown, Tex.), 2016
TP53 mutants in the tower of babel of cancer progression.
Bisio A et al.
Human Mutation, 2014
Reversal of the DNA-binding-induced loop L1 conformational switch in an engineered human p53 protein.
Emamzadah S et al.
Journal of Molecular Biology, 2014
Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
Ciribilli Y et al.
Nucleic Acids Research, 2013
Overexpression of DRAM enhances p53-dependent apoptosis.
Takahashi M et al.
Cancer Medicine, 2013
Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics.
Lukman S et al.
Plos One, 2013
Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53.
Yasuda K et al.
Oncology Letters, 2012
Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A et al.
The Biochemical Journal, 2010
Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.
Ahn J et al.
Cell Cycle (georgetown, Tex.), 2009
Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts.
Noureddine MA et al.
Plos Genetics, 2009
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H et al.
Cancer Research, 2009
Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.
Pietsch EC et al.
The Journal of Biological Chemistry, 2008
Novel variants in growth differentiation factor 9 in mothers of dizygotic twins.
Palmer JS et al.
The Journal of Clinical Endocrinology and Metabolism, 2006
Mutational analysis of the p53 core domain L1 loop.
Zupnick A et al.
The Journal of Biological Chemistry, 2006
Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis.
Nakamura Y et al.
Cancer Science, 2006
p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A et al.
Oncogene, 2001
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
Han SY et al.
Cancer Research, 2000
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.
Brachmann RK et al.
The Embo Journal, 1998